Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06234527
Other study ID # LRP23021-D serum
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2024
Est. completion date August 2024

Study information

Verified date January 2024
Source Cosmetique Active International
Contact Fatimata LY
Phone +221 77 559 97 41
Email lyfaty@yahoo.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.


Description:

Hyperpigmentation is a common skin condition in which the color of the skin becomes darker. These changes result from an excess of melanin production, distribution, or transport which can be caused by various internal and external factors such as genetic predisposition, hormonal changes, inflammation, acne, ultraviolet (UV) exposure. Typical hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma and solar lentigines. This open, single-centre, three-arm study is carried out with a new cosmetic formulation developed with the aim of acting on facial hyperpigmentation and used under normal conditions of use with before/after comparisons. This clinical trial is conducted in accordance with the protocol, the HELSINKI declaration (1964) and subsequent amendments, and/or the International Council on Harmonization (ICH) Good Clinical Practices (GCP)/ and in compliance with applicable regulatory requirements. Statistical Analysis: - Efficacy Analysis: in each group, the quantitative parameters are analyzed using a mixed-effect model. This model includes Time and baseline as fixed effects. Patient are added as random effect. The comparisons between post-baseline time-point and baseline are performed whatever the interaction results using a Dunnett adjustment. Degrees of freedom for the comparisons are approximated by the Kenward-Roger method. - Safety Analysis: no statistical analysis will be performed on safety. The data are presented descriptively. Categorical data are summarized using the number and percentage of patients in each category. Continuous data are summarized using the arithmetic mean, Standard Deviation (SD), Q1, Q3, minimum, median and maximum values. Regarding the sample size determination, there was no formal calculation. A number of 20 patients in each group (i.e. 60 patients in total) was considered sufficient to meet the study objective.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - all phototypes - only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo - female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study - patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study Exclusion Criteria: - female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study - male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline) - patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc. - severe melasma, dermal melasma - patient with facial pigmentary disorders other than those described in inclusion criteria - patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0/Baseline visit - patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0/Baseline visit; - patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0/Baseline visit

Study Design


Related Conditions & MeSH terms


Intervention

Other:
tested product
application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months

Locations

Country Name City State
Senegal Institut d'Hygiène Sociale de Dakar Dakar

Sponsors (1)

Lead Sponsor Collaborator
Cosmetique Active International

Country where clinical trial is conducted

Senegal, 

Outcome

Type Measure Description Time frame Safety issue
Primary IGA score for patients with melasma or acne induced post-inflammatory hyperpigmentation (PIHP) The hyperpigmentation is measured on a scale from 0 (cleared, almost cleared) to 3 (markedly darker than the surrounding normal skin). from baseline to Day84
Primary modified Melasma Area and Severity Index (mMASI) for patients with melasma the mMASI is calculated using 3 components: four regions (forehead, right malar, left malar and chin); area of involvement for each region (using a scale from 0 to 6); darkness compared to the surrounding normal skin for each area (evaluated using a scale from 0 to 6). from baseline to Day 84
Primary Post-Acne Hyperpigmentation Index (PAHPI) The PAHPI total score is the sum of all 3 weighted scores: median lesion size (form 2 [< 3mm] to 8 [> 10mm], median lesion intensity (from 3 [slightly darker than surrounding skin] to 9 [significantly darker than surrounding skin] and number of lesions (from 1 [1-15] to 5 [> 60]. Total score ranges from 6 to 22. from baseline to Day 84
Primary solar lentigo pigmentation scale The solar lentigo pigmentation scale evaluates the pigmentation using the following scale: from 0 (no pigmentation) to 10 (brown+). from baseline to Day84
Secondary colorimetry measurements Skin color is measured using the L*a*b* color space (L* represents lightness, a* its position between green and red, b* its position between blue and yellow). from baseline to Day84
Secondary stigmatization questionnaire The patients are asked to answer the 17 questions of the stigmatization questionnaire using six different responses: very often, often, sometimes, rarely, never, not concerned. from baseline to Day84
Secondary local tolerability assessment by the investigator The clinical signs (erythema, dryness and desquamation) are evaluated using 5-point rating scales: from 0 (no signs of irritation (no erythema/dryness/desquamation)) to 3 (severe signs of irritation (erythema/dryness/desquamation)). Day28; Day56; Day84
Secondary local tolerability assessment by the patient the subjective symptoms (itching/tingling/burning sensation) are evaluated using 5-point rating scales: from 0 (no itching/tingling/burning sensation) to 3 (severe itching/tingling/burning sensation). Day28; Day56; Day84
See also
  Status Clinical Trial Phase
Completed NCT04586816 - Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging N/A
Completed NCT06000839 - A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology) N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT05362929 - Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color N/A
Completed NCT06031116 - Efficacy of Ceramic Soft Tissue Trimming Bur Versus Conventional Scalpel Technique in Ginigival Depigmentation Procedure N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Active, not recruiting NCT05493280 - Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI N/A
Recruiting NCT06253455 - Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins N/A
Not yet recruiting NCT06080035 - The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation N/A
Completed NCT03457246 - Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Recruiting NCT05165524 - Brightening Cream and Lasers in Post-sclerotherapy Hyperpigmentation N/A
Not yet recruiting NCT06268496 - Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins N/A
Not yet recruiting NCT06253468 - Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins N/A
Completed NCT05423873 - A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging N/A
Completed NCT01149876 - Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Phase 4
Completed NCT01542138 - Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation Phase 4
Completed NCT04704245 - Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines N/A
Completed NCT06189768 - A Study on Pigmentation Disorders in Children
Completed NCT06103461 - Fat Grafting an Ideal Filler For Contour Deformities With Hyperpigmentation On Face N/A